Atazanavir
- Generic Name
- Atazanavir
- Brand Names
- Evotaz, Reyataz, Atazanavir Krka, Atazanavir Viatris (previously Atazanavir Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C38H52N6O7
- CAS Number
- 198904-31-3
- Unique Ingredient Identifier
- QZU4H47A3S
- Background
Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the pa...
- Indication
Atazanavir is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients 3 months of age and older weighing at least 5kg. Atazanavir is also indicated in combination with cobicistat and other antiretrovirals for the treatment of HIV-1 infection in adults and pediatric patients weighing at l...
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
Atazanavir or Boosted Atazanavir Substitution for Ritonavir Boosted PI in Patients With Hyperlipidemia
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2011-07-21
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 60
- Registration Number
- NCT00160329
- Locations
- ๐บ๐ธ
Stanford University School of Medicine, Stanford, California, United States
Efficacy and Safety of Tenofovir DF/Atazanavir Enhanced With Low Dose of Ritonavir in HIV-Infected Patients
- Conditions
- First Posted Date
- 2005-07-22
- Last Posted Date
- 2005-07-28
- Target Recruit Count
- 50
- Registration Number
- NCT00122577
- Locations
- ๐ซ๐ท
Service d'Immunologie clinique Hopital Europeen Georges Pompidou, Paris, France
Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults
- First Posted Date
- 2005-07-12
- Last Posted Date
- 2018-10-12
- Target Recruit Count
- 1864
- Registration Number
- NCT00118898
- Locations
- ๐บ๐ธ
Univ of Iowa Hosp and Clinic (1504), Iowa City, Iowa, United States
๐บ๐ธVanderbilt Therapeutics CRS (3652), Nashville, Tennessee, United States
๐บ๐ธSUNY - Buffalo (Rochester) (1102), Buffalo, New York, United States
Safety, Tolerability, and Blood Levels of Ritonavir-Boosted Atazanavir and Rifampin When Taken Together in HIV Uninfected Adults
- Conditions
- Interventions
- First Posted Date
- 2004-11-17
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 18
- Registration Number
- NCT00096850
- Locations
- ๐บ๐ธ
Vanderbilt Therapeutics CRS, Nashville, Tennessee, United States
๐บ๐ธThe Ohio State Univ. AIDS CRS, Columbus, Ohio, United States
๐บ๐ธStanford CRS, Palo Alto, California, United States
Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings
- First Posted Date
- 2004-06-08
- Last Posted Date
- 2018-10-10
- Target Recruit Count
- 1571
- Registration Number
- NCT00084136
- Locations
- ๐บ๐ธ
University of Texas, Galveston, Galveston, Texas, United States
๐ฒ๐ผCollege of Med. JHU CRS, P.O. Box 1131, Blantyre, Malawi
๐ฟ๐ผUZ-Parirenyatwa CRS, AIDS Research Unit P.O. Box A178, Harare, Zimbabwe
Atazanavir/Ritonavir Maintenance Therapy
- Conditions
- First Posted Date
- 2004-06-07
- Last Posted Date
- 2021-11-01
- Target Recruit Count
- 36
- Registration Number
- NCT00084019
- Locations
- ๐บ๐ธ
University of Pittsburgh CRS, Pittsburgh, Pennsylvania, United States
๐บ๐ธDallas VAMC, Dallas, Texas, United States
๐บ๐ธUniversity of Colorado Hospital CRS, Aurora, Colorado, United States
A Study Comparing The Safety, Tolerability and Efficacy of Trizivir VS Combivir & Atazanavir In Subjects With HIV
- Conditions
- First Posted Date
- 2004-05-10
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00082394
- Locations
- ๐ฒ๐ฝ
GSK Investigational Site, Monterrey, Nuevo Leรณn, Mexico
Preventing Sexual Transmission of HIV With Anti-HIV Drugs
- First Posted Date
- 2003-12-17
- Last Posted Date
- 2021-11-05
- Target Recruit Count
- 3526
- Registration Number
- NCT00074581
- Locations
- ๐บ๐ธ
Fenway Community Health Ctr. CRS, Boston, Massachusetts, United States
๐ง๐ผGaborone CRS, Gaborone, Botswana
๐ง๐ทHospital Geral de Nova Iguaรงu CRS (HGNI CRS), Nova Iguacu, Rio De Janeiro, Brazil
Atazanavir Versus Lopinavir/Ritonavir (LPV/RTV) in Patients Who Have Not Had Success With Protease Inhibitor-Containing HAART Regimen(s)
- Conditions
- First Posted Date
- 2001-12-21
- Last Posted Date
- 2010-09-13
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT00028301
- Locations
- ๐ง๐ช
University Hospital Gent, Gent, Belgium
๐ฆ๐ทCAICI, Rosario Santa Fe, Argentina
๐ง๐ชCHU Saint Pierre, Brussels, Belgium
A Comparison of Atazanavir and Nelfinavir, Each in Combination With 2 NRTIs, in Patients Who Have Failed Treatments Without a Protease Inhibitor
- Conditions
- First Posted Date
- 2001-12-11
- Last Posted Date
- 2011-05-04
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 500
- Registration Number
- NCT00028067
- Locations
- ๐น๐ญ
Ramathibodi Hosp, Bangkok, Thailand
๐น๐ญKhonkaen Univ, Khonkaen, Thailand
๐บ๐ธHealth for Life Clinic, Little Rock, Arkansas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.